CAPR Capricor Therapeutics: Year-over-year earnings per share growth for the last twelve months

Official company branding of Capricor Therapeutics Inc. (CAPR)

The optimization of biomaterial delivery chains is driving a quarterly EPS growth trend, where the current value is -37.20. The foundation of Capricor Therapeutics (CAPR) success is based on global distribution alliances for its drugs and the synergy of clinical trials. Leading cell therapy specialists, motivated by the fight against cardiac pathologies and an innovative approach to treatment, ensure the business efficiency.

Capricor Therapeutics, Inc. (CAPR) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/14/2026

Analytical breakdowns for Capricor Therapeutics

- share price and consensus valuation forecast:
Stock Quotes capricor.com|CAPR - Analyst Consensus Forecast
- company stock capitalization data:
Market Value Capricor|CAPR - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share Capricor Therapeutics|CAPR - Total Stockholders' Equity|Market Value to Book Value Ratio capricor.com|CAPR - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity Capricor Therapeutics|CAPR - Long-Term Liabilities to Capital|Short-Term Debt to Capital capricor.com|CAPR - Company Total Indebtedness|Debt to Book Value Capricor|CAPR - Long-Term Debt|Company Short-Term Debts Capricor Therapeutics|Quick Ratio capricor.com
- earnings and market multiples details:
CAPR - Net Profit|Expected Profit Capricor Therapeutics|CAPR - Market Cap to Net Income|Future Price to Earnings capricor.com|CAPR - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Capricor|CAPR - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Capricor Therapeutics|CAPR - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months capricor.com|CAPR - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Capricor Therapeutics
- sales volume and revenue indicators:
CAPR - Company Sales Revenue|Company Future Sales Volume capricor.com|CAPR - Market Capitalization-to-Revenue Ratio|Forward Price-to-Revenue Multiple Capricor
Fundamental company analysis:Capricor Therapeutics Inc., CAPR
Manufactured product of Capricor Therapeutics

The stability of Capricor Therapeutics (CAPR) relies on the synergy between highly qualified scientists and innovative developments in cardiology. This metric captures the dynamics of net income per share, stripping the financial result of one-time anomalies and market noise. Investors should evaluate real operational efficiency while ignoring short-term price fluctuations. The fundamental trend reflects the impact of costs on business margins. Analyzing the volatility of the quarterly EPS allows for an objective assessment of the capitalization of the team's intellectual potential.

Analysis of competing companies

JAZZ (Jazz Pharmaceuticals plc) - Year-over-year net earnings per share growth for the last 12 months|Cytokinetics Inc. (CYTK) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months PTC Therapeutics Corp|SRRK: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Centessa Pharmaceuticals (CNTA)|DYN - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Edgewise Therapeutics, Inc. EWTX|Rapport Therapeutics Inc - Year-over-year earnings per share growth for the last twelve months|ALMS - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Zevra Corp|CTNM: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year larimartx.com LRMR|Year-over-year net earnings per share growth for the last 12 months TRDA|Earnings per share growth in annualized terms for the last twelve months Channel Therapeutics Inc. PTHS|Quarterly EPS earnings growth MNOV|Year-over-year net earnings per share growth for the last 12 months Serina Pharma SER|Quarterly EPS earnings growth BTAI (BioXcel Therapeutics)|Quarterly EPS earnings growth ProMIS Neurosciences Inc. PMN|APUS - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share trend for the last twelve months AEON|nlspharma.com (NLSP) - Year-over-year earnings per share growth for the last twelve months|Bionomics - Year-over-year earnings per one share growth for the last 12 months|HUGE (FSD Pharma Inc.) - Quarterly EPS earnings growth|reatapharma.com (RETA) - Year-over-year net earnings per share change for the last twelve months